Bruce - would post a longer response on merits of CTIX (heading up to slopes soon) but others have made good points... Thx btw. For me there's no comparison with what we have in the Defensin mimetic portfolio -- Id recommend him reviewing all the clinical work advanced by PYMX... They were simply ahead of the curve as to biomemetic compounds. Again the IBM Rsch lab guys are playing catchup as are researchers out of MD and Ohio State. My post on Brilacidin Approval Odds I think reinf the likelihood that B will get thumbs up for ABSSSI.
News 
Market Data 
Discover 
